Stockreport

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines, Inc.  (RVMD) 
PDF Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for dat [Read more]